Dee Datta is the founder of Switch Therapeutics. Switch Therapeutics has raised $52M in total funding. Latest round: Series A.
Dee Datta is the co-founder and CEO of Switch Therapeutics, a preclinical stage biotechnology company based in South San Francisco, California. The company focuses on pioneering new RNA science to treat diseases, utilizing its proprietary CASi (Conditionally Activated siRNA) molecules. Switch Therapeutics recently launched with $52 million in Series A financing, co-led by Insight Partners and UCB Ventures. Datta pursued her Ph.D. at Caltech and has prior experience launching companies.
Full founder directory · Investor directory · Company funding database · Fundraising library